Medartis Holding AG (SIX: MED) announced that at its Annual General Meeting held on April 23, 2026, shareholders approved all substantive proposals of the Board of Directors with majorities exceeding 90.9%. The meeting, held at the company's headquarters in Basel, saw significant shareholder participation with 77.4% of total share capital represented, totaling 10,545,669 shares.
All seven members of the Board of Directors standing for re-election received overwhelming endorsement, each securing more than 93.8% support from represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee. Chairman Marco Gadola will continue to lead the board. Shareholders granted discharge to board members for their governance during the 2025 term and approved the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board through separate votes.
The 2025 management report and annual financial statements received nearly unanimous approval (99.99%), while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement with 99.2% of represented shares, confirming Medartis' commitment to transparent ESG practices. Shareholders also confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors.
After two years with Medartis, Jennifer Dean decided not to stand for re-election. The assembly confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee, ensuring continuity in oversight of the company's human capital strategy. As of the AGM, the Medartis Board of Directors comprises Marco Gadola (Chairman), Dr. h.c. Thomas Straumann (Vice Chairman), Willi Miesch, Damien Tappy, Nadia Tarolli Schmidt, Ciro Roemer, Martha Shadan, and Yang Xu.
Medartis also confirmed upcoming dates for its investor and corporate calendar. On June 4, 2026, Medartis will host an investor event in Basel on the fringes of the FESSH Hand Surgery Congress, open to institutional investors. The first-half 2026 results will be published on August 18, 2026, followed by an analyst and media briefing. The next Annual General Meeting is scheduled for April 22, 2027 at the company's headquarters in Basel.
For a detailed listing of all resolutions at the 2026 Annual General Meeting, visit this link. More information about Medartis is available at www.medartis.com.
